Since the genetic profile guided treatment was widely used in metastatic NSCLC, the molecular variations rarely affected primary treatment options for stage III patients yet, thus EGFR mutation data was not obtained in 40 (33.1%) patients in the training group. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.